 Shared health Soins communs Manitoba	M09 - FUROSEMIDE (LASIX)	
	Version date: 2025-02-06	Effective date: 2025-04-30 (07:00)



INDICATIONS
<ul style="list-style-type: none"> Heart failure with evidence of pulmonary edema

WARNINGS
ABSOLUTE CONTRAINDICATIONS: <ul style="list-style-type: none"> Hypersensitivity to furosemide or sulfonamides Hypotension / hypoperfusion / shock

ADMINISTRATION	
INTRAVENOUS (INTRAOSSEOUS)	ICP / ACP
ADULTS: <ul style="list-style-type: none">• <i>Not currently on furosemide</i> - 20 to 40 mg• <i>Currently on furosemide</i> - 40 to 80 mg• Administer by slow push over 1 to 2 minutes• No repeat dosing	

NOTES
<ol style="list-style-type: none"> Although the safety and efficacy of diuretics to treat acute decompensated heart failure (ADHF) have not been established, extensive observational experience has demonstrated that are effective in relieving congestive symptoms in pulmonary edema and are essential for the successful treatment of most patients with ADHF and volume overload.

LINKS
<ul style="list-style-type: none"> E08 - Decompensated Heart Failure & Cardiogenic Pulmonary Edema

APPROVED BY	
	
Provincial Medical Director	Associate Provincial Medical Director

VERSION CHANGES (refer to X08 for change tracking)
<ul style="list-style-type: none"> • Addition of ACP work scope